In a filing, Taysha Gene Therapies Inc revealed its President and Head of R&D Nagendran Sukumar unloaded Company’s shares for reported $0.65 million on Sep 10 ’25. In the deal valued at $3.23 per share,200,000 shares were sold. As a result of this transaction, Nagendran Sukumar now holds 1,006,439 shares worth roughly $3.04 million.
Then, Nagendran Sukumar bought 200,000 shares, generating $652,000 in total proceeds.
Before that, Nagendran Sukumar sold 57,054 shares. Taysha Gene Therapies Inc shares valued at $162,604 were divested by the President and Head of R&D at a price of $2.85 per share. As a result of the transaction, Nagendran Sukumar now holds 1,165,289 shares, worth roughly $3.52 million.
BofA Securities initiated its Taysha Gene Therapies Inc [TSHA] rating to a Buy in a research note published on July 11, 2025; the price target was $8. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in late June with a ‘”an Outperform”‘ rating. Piper Sandler began covering TSHA with “an Overweight” recommendation on April 09, 2024. Jefferies revised its rating on February 01, 2023. It rated TSHA as “a Hold” which previously was an “a Buy”.
Price Performance Review of TSHA
On Monday, Taysha Gene Therapies Inc [NASDAQ:TSHA] saw its stock fall -1.63% to $3.02. Over the last five days, the stock has lost -6.79%. Taysha Gene Therapies Inc shares have risen nearly 30.17% since the year began. Nevertheless, the stocks have risen 74.57% over the past one year.
How much short interest is there in Taysha Gene Therapies Inc?
A steep rise in short interest was recorded in Taysha Gene Therapies Inc stocks on 2025-08-29, growing by 2.57 million shares to a total of 40.78 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 38.21 million shares. There was a rise of 6.29%, which implies that there is a positive sentiment for the stock.
